Extract Or Material Containing Or Obtained From A Micro-organism As Active Ingredient (e.g., Bacteria, Protozoa, Etc.) Patents (Class 424/780)
-
Patent number: 8932844Abstract: The invention induces an increase in the resistance of potato plants, without apparent toxicity for the plant. Preliminary experiments indicate that the increase in metabolism of plants efficiently fosters (above 60%) the reduction of the development of the pathogenic phytobacteria, Erwinia carotovora, one of the principal agents in causing diseases in potatoes.Type: GrantFiled: October 19, 2013Date of Patent: January 13, 2015Assignee: Uniao Brasileira de Educacao e Assistencia—Mantenedora da PUCRSInventors: Leandro Vieira Astarita, Fernando Rostirolla Dalmas, Vera Aparecida Dus Poiatti
-
Patent number: 8933193Abstract: The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics.Type: GrantFiled: May 3, 2011Date of Patent: January 13, 2015Assignee: Regents of the University of MinnesotaInventors: Daniel J. O'Sullivan, Ju-Hoon Lee
-
Publication number: 20140348878Abstract: A strain of exopolysaccharide-secreting Lactobacillus brevis, BDLB0001, and an application thereof. The Lactobacillus brevis is deposited at the China General Microbiological Culture Collection Center of the China Committee of Culture Collection for Microorganisms, with a deposit number of CGMCC No. 5223. The Lactobacillus brevis secrets an elevated amount of exopolysaccharide, where the exopolysaccharide secreted is capable of eliciting B lymphocyte proliferation to enhance immunity, and has application prospects in medicaments, healthcare products and food products for immunity enhancement.Type: ApplicationFiled: April 25, 2012Publication date: November 27, 2014Applicant: BRIGHT DAIRY & FOOD CO., LTD.Inventors: Lianzhong Ai, Benheng Guo, Kejie Sun, Wei Chen, Hao Zhang, Li Shao, Zhengjun Wu, Wanyi Chen, Haibo Mu
-
Publication number: 20140341921Abstract: Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.Type: ApplicationFiled: November 29, 2012Publication date: November 20, 2014Applicants: The University of Tokyo, School Corporation , Azabu Veterinary Medicine Educational InstitutionInventors: Kenya Honda, Koji Atarashi, Takeshi Tanoue, Masahira Hattori, Hidetoshi Morita
-
Publication number: 20140341852Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations containing them. Also provided are methods of preparing and using the disclosed capsid-protein-mutated rAAV constructs in a variety of diagnostic and therapeutic modalities, including, inter alia, as mammalian cell-targeting delivery agents, and as human gene therapy vectors. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: ApplicationFiled: March 14, 2014Publication date: November 20, 2014Applicant: University of Florida Research Foundation, Inc.Inventors: Arun Srivastava, George V. Aslanidi, Sergei Zolotukhin, Mavis Agbandje-McKenna, Kim M. Van Vliet, Li Zhong, Lakshmanan Govindasamy
-
Patent number: 8883227Abstract: Combinations, compositions and methods of use for modulating plant pathogen infection using plant extracts containing anthraquinone derivatives which induce resistance to plant phytopathogens and an antimicrobial agent, a biological control agent and/or a surfactant having fungicidal activity.Type: GrantFiled: November 15, 2013Date of Patent: November 11, 2014Assignee: Marrone Bio Innovations, Inc.Inventors: Hai Su, Marja Koivunen, Pamela Marrone
-
Publication number: 20140328802Abstract: The invention relates to a new strain of Lactobacillus mucosae which is able to decrease intestinal barrier permeability. This strain is useful in particular for alleviating intestinal barrier dysfunctions.Type: ApplicationFiled: December 21, 2011Publication date: November 6, 2014Inventors: Tamara Smokvina, Marie-Christine Degivry
-
Publication number: 20140322307Abstract: The present invention refers to a peptide of general formula (I) R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2, cosmetic compositions which comprises said peptide, method of preparation of said peptides and its use in the treatment and/or prevention of itching, inflammation, pain, diseases and/or disorders of the respiratory airways.Type: ApplicationFiled: October 31, 2012Publication date: October 30, 2014Inventors: Antonio Vicente Ferrer Montiel, José María García Antón, Raquel Delgado González
-
Publication number: 20140322372Abstract: The present invention relates to novel bacterial and mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity.Type: ApplicationFiled: February 25, 2014Publication date: October 30, 2014Applicant: BIONICHE UROLOGY IP INC.Inventors: Nigel C. Phillips, Danbing Ke, Zdenek Richard Holan, Mario C. Filion, Mohamed Elrafih, Iqubal Velji
-
Publication number: 20140322186Abstract: To provide a pharmaceutical product or food which has an excellent fat-accumulation-inhibiting activity and/or fat-metabolism-improving activity and which is effective for inhibition or improvement of obesity, fatty liver, etc. The present invention provides an agent for preventing or ameliorating obesity containing, as an active ingredient, cells of a lactic acid bacterium belonging to the genus Pediococcus, a cell culture thereof, or an extract of any of these.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Applicant: HIROSHIMA UNIVERSITYInventors: Masanori Sugiyama, Fumiko Higashikawa, Masafumi Noda
-
Publication number: 20140322171Abstract: Provided is the use of or compositions or formulations comprising Chromobacterium species, filtrate, supernatant, extract, pesticidally active compound or metabolite derived therefrom as an insecticide, particularly against infestation of Corn Rootworm larvae.Type: ApplicationFiled: July 14, 2014Publication date: October 30, 2014Inventors: Lina Flor-Weiler, April Yang
-
Publication number: 20140322172Abstract: This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus Lactobacillus and the genus Bifidobacterium, a treated product of the bacterial cell, or a mixture thereof, having dual-agonistic activities to peroxisome proliferator activated receptor (PPAR)? and peroxisome proliferator activated receptor (PPAR)?; to a food or a beverage comprising the improver; and to a pharmaceutical composition comprising the improver.Type: ApplicationFiled: December 6, 2012Publication date: October 30, 2014Applicant: CALPIS CO., LTD.Inventors: Futoshi Nakamura, Nobuhisa Ashida, Yu Ishida, Shigeru Fujiwara
-
Publication number: 20140314890Abstract: Discloses herein is a combination therapy for treating cancer by administration of a phycocyanin and a chemotherapeutic.Type: ApplicationFiled: October 30, 2012Publication date: October 23, 2014Applicants: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES, NOVA SOUTHEASTERN UNIVERSITYInventors: Miroslav Gantar, Appu Rathinavelu, Sivanesan Dhandayuthapani
-
Publication number: 20140314718Abstract: The present invention relates to an isolated strain of Bacillus subtilis (IAB/BS/03) deposited at the DSM German Type Culture Collection under Access No DSM 24682, or a mutant of said strain, and also deposited at the Spanish type culture collection under Access number CECT 7254, the property of the company filing the patent, in which said strain and/or the mutant thereof exhibits antifungal and antibacterial activity, with a profile of action different from that of other strains of Bacillus subtilis and with much greater potency in terms of the capacity thereof to act as a field biological control agent. The invention also includes methods for preventing and treating fungal and bacterial diseases in plants using said bacterial strains or supernatants containing antibiotics or pure antibiotics obtained from said bacterial strains, in which said antibiotics are contained in a composition.Type: ApplicationFiled: May 4, 2012Publication date: October 23, 2014Inventors: Estefania Hinarejos Esteve, Raquel Del Val Buedo, Nuria Tarancon Valera, Enrique Riquelme Terres
-
Publication number: 20140309107Abstract: The present invention relates to a composition comprising at least one biological control agent selected from the group consisting Bacillus subtilis AQ713 (NRRL Accession No. B-21661), Bacillus subtilis AQ30002 (NRRL Accession No. B-50421), and Bacillus subtilis AQ 30004 (NRRL Accession No. B-50455), and/or a mutant of these strains having all the identifying characteristics of the respective strain, and/or a metabolite produced by the respective strain that exhibits activity against insects, mites, nematodes and/or phytopathogens and at least one fungicide (I) selected from the group consisting of inhibitors of amino acid and/or protein biosynthesis and inhibitors of cell wall synthesis in a synergistically effective amount. Furthermore, the present invention relates to the use of this composition as well as a method for reducing overall damage of plants and plant parts.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventors: Ulrike WACHENDORFF-NEUMANN, Wolfram ANDERSCH, Bernd SPRINGER, Klaus STENZEL
-
Publication number: 20140295012Abstract: Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-fB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-fB activity without a second delayed increase in NF-fB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). The HRF can, for example, comprise a Massilia flagellin polypeptide or fragment thereof. Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.Type: ApplicationFiled: November 15, 2012Publication date: October 2, 2014Inventors: Olaf Kutsch, Frank Wolschendorf
-
Publication number: 20140271763Abstract: Disclosed herein are marine bacterial substances, methods, and medical devices that inhibit biofilm growth and/or formation. Substances of the present disclosure are products or byproducts of P3-2 (ATCC PTA-6763), P4-4 (ATCC PTA-6682), P5-2 (ATCC PTA-6764), or P6-6 (ATCC PTA-6766) marine bacterial isolates.Type: ApplicationFiled: April 29, 2014Publication date: September 18, 2014Inventor: Cynthia K. Burzell
-
Publication number: 20140271553Abstract: The present disclosure relates to nutritional compositions comprising a protein equivalent source, wherein 20% to 80% of the protein equivalent source includes a peptide component comprising SEQ ID NO 4, SEQ ID NO 13, SEQ ID NO 17, SEQ ID NO 21, SEQ ID NO 24, SEQ ID NO 30, SEQ ID NO 31, SEQ ID NO 32, SEQ ID NO 51, SEQ ID NO 57, SEQ ID NO 60, and SEQ ID NO 63, and 20% to 80% of the protein equivalent source comprises an intact protein, a partially hydrolyzed protein, or combinations thereof. The disclosure further relates to methods of reducing the inflammatory response and/or production of proinflammatory cytokines, i.e. Interleukin-17, by providing said nutritional compositions to a target subject.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Mead Johnson Nutrition (Asia Pacifci) Pte. Ltd.Inventors: Dirk Hondmann, Eric A.F. van Tol, Gabriele Gross, Marieke H. Schoemaker, Teartse Tim Lambers
-
Publication number: 20140248246Abstract: The present invention relates to edible webs comprising microorganisms, such as probiotics. In particular, the present invention relates to an edible web having microorganisms, such as bacteria, probiotic bacteria, bacteriophages or viruses printed thereon, e.g. by the use of inkjet printing. In addition the invention relates to methods of producing such edible webs, to various products comprising the edible webs as well as to use of the edible webs comprising microorganisms.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Inventor: Martinas Kuslys
-
Publication number: 20140234379Abstract: This invention provides an IFN inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing IFN production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such IFN inducer and having IFN-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing IFN production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pDCs) and promote IFN production, such as Lactococcus garvieae NBRC100934, Lactococcus lactis subsp. cremoris JCM16167, Lactococcus lactis subsp. cremoris NBRC100676, Lactococcus lactis subsp. hordniae JCM1180, Lactococcus lactis subsp. hordniae JCM11040, Lactococcus lactis subsp. lactis NBRC12007, Lactococcus lactis subsp. lactis NRIC1150, Lactococcus lactis subsp. lactis JCM5805, Lactococcus lactis subsp.Type: ApplicationFiled: April 28, 2014Publication date: August 21, 2014Applicant: KIRIN HOLDINGS KABUSHIKI KAISHAInventors: Daisuke Fujiwara, Kenta JONAI, Tetsu SUGIMURA
-
Publication number: 20140234371Abstract: The present invention relates to a gram positive bacterium, preferably a lactic acid bacterium (LAB) or Bifidobacterium, with increased stress resistance and/or improved manufacturing, processing and/or storage characteristics. In particular, the invention relates to a gram positive bacterium which accumulate intracellular trehalose. The gram positive bacterium according to the invention lack trehalose 6-phosphate phosphorylase (TrePP) activity. The gram positive bacterium may further lack cellobiose-specific PTS system IIC component (ptcC) activity. The gram positive bacterium may further overexpress trehalose transporters. The invention further relates to compositions comprising such gram positive bacterium as well as methods and uses thereof.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Inventors: Lothar Steidler, Karolien Van Huynegem, Klaas Vandenbroucke
-
Publication number: 20140221207Abstract: A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, algae, arachnids, insects, fungi, weeds and nematodes) as well as methods for controlling algae using said species of Burkholderia. Also provided are natural products derived from a culture of said species and methods of controlling algae and/or arachnids using said natural products.Type: ApplicationFiled: August 14, 2012Publication date: August 7, 2014Applicant: MARRONE BIO INNOVATIONS, INC.Inventors: Ratnakar Asolkar, Marja Koivunen, Pamela Marrone
-
Publication number: 20140220070Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: ApplicationFiled: December 23, 2013Publication date: August 7, 2014Applicant: Thylabisco ABInventors: Per-Ake ALBERTSSON, Charlotte ERLANSSON-ALBERTSSON
-
Patent number: 8790725Abstract: This invention relates to compositions and methods for improving water quality by enhancing natural bacterial processes and altering environmental conditions in situ. This is achieved by the manufacture and use of granules or tablets composed of the inventive formulations.Type: GrantFiled: May 17, 2007Date of Patent: July 29, 2014Assignee: Aqua Dynamic Solutions, LLCInventor: John W. Dituro
-
Publication number: 20140205693Abstract: The present invention relates to an extract from bacterial strains, such as Staphylococcus, Moraxella, Klebsiella, Streptococcus, and Haemophilus. The extract is useful as a treatment for indications such as respiratory disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.Type: ApplicationFiled: March 20, 2014Publication date: July 24, 2014Applicant: OM PHARMA SAInventors: Jacques Alain BAUER, Marco SALVAGNI, Jean-Pierre Leon VIGROUX, Laetitia CHALVET, Carlo CHIAVAROLI
-
Publication number: 20140199267Abstract: The invention provides methods for using fatty acid alkanolamides for ameliorating one or more symptoms or conditions caused by stress, e.g., loss of appetite, or for maintaining and enhancing nutrient and caloric intake by an animal under stress or that has experienced stress. Generally, the fatty acid alkanolamides in amounts of from about 0.1 to about 1500 mg/kg/day before, during or after stress, preferably on a regular or daily basis as a component of a food composition or as a dietary supplement.Type: ApplicationFiled: August 7, 2012Publication date: July 17, 2014Applicant: Nestec SAInventors: Delphine Tissot-Favre, Yuanlong Pan
-
Publication number: 20140199269Abstract: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Marrone Bio Innovations, Inc.Inventors: Ratnakar Asolkar, Huazhang Huang, Marja Koivunen, Pamela Marrone
-
Publication number: 20140194287Abstract: A crushed bacterial body can be obtained by culturing a gram-negative bacterium and physically crushing a body of the gram-negative bacterium, comprises all components including immunostimulatory components in the bacterial body, and comprises LPSs having molecular weights of 20,000 or less as active ingredients. The crushed bacterial body is effective as a health food, drug, skin-care product, bath agent, feedstuff for protecting crustaceans, shellfish, fish, poultry, farm animals and pet animals from infections, and a feed additive for growth promotion, and can provide an innate immunostimulatory substance derived from a gram-negative bacterial body having infection-preventing effects and growth promoting effects, an inexpensive and practical microbial crushed bacterial body, and a composition thereof.Type: ApplicationFiled: June 14, 2012Publication date: July 10, 2014Applicants: SOMA, GEN-ICHIRO, BioMedical Research Group Inc.Inventors: Gen-Ichiro Soma, Hiroyuki Inagawa, Chie Kohchi
-
Publication number: 20140193371Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Inventor: Harold Edward Siess
-
Publication number: 20140186409Abstract: The invention relates to a microorganism, of the order of lactic acid bacteria or analog, fragment, derivative, mutant or combination thereof. Said microorganism, or analog, fragment, derivative, mutants or combinations thereof can be co-aggregated with at least Staphylococcus aureus or Pseudomonas aeruginosa.Type: ApplicationFiled: May 7, 2012Publication date: July 3, 2014Applicant: ORGANOBALANCE MEDICAL AGInventors: Christine Lang, Andreas Raab, Patrick Golletz
-
Publication number: 20140186475Abstract: The invention discloses a bacterial strain of non pathogenic Cobetia marina useful in aquaculture, corresponding to an isolated Cobetia marina strain, Gram negative, oxidase positive, deposited under registry number CECT N° 7764; grows with dibenzothiophene (DBT) as the only carbon source. Also disclosed is a method to obtain a biosurfactant surfactant extract comprising growing strain Cobetia marina (MM1IDA2H-1) CECT N° 7764 in a reactor with liquid growth medium from 24 to 48 hours at a temperature between 10 and 35° C., pH 6 to 8; constant stirring between 100 to 400 rpm and oxygen saturation between 10 to 21%; until obtaining a grown cell culture and extracellular products plus inorganic salts; separating the cells, lyophilizing supernatant, sieve the obtained powder and dry.Type: ApplicationFiled: May 30, 2012Publication date: July 3, 2014Applicant: UNIVERSIDAD DE VALPARAISOInventors: Miguel Alejandro Dinamarca Tapia, Juan Ricardo Ojeda Herrera, Claudia Jimena Ibacache Quiroga
-
Patent number: 8765118Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.Type: GrantFiled: August 11, 2011Date of Patent: July 1, 2014Assignee: Chr. Hansen A/SInventors: Christel Garrigues, Martin Bastian Pedersen
-
Publication number: 20140178512Abstract: The present invention pertains to a method for the in situ preparation of a filler, comprising the step of applying a polyanionic biopolymer solution at an application site below the dermis of a patient for restoring volume at said application site, wherein the polyanionic biopolymer is selected from pectin and gellan. Furthermore, the present invention pertains to a kit comprising (i) a polyanionic biopolymer solution; and (ii) a solution comprising at least one divalent cation.Type: ApplicationFiled: February 17, 2012Publication date: June 26, 2014Applicant: MERZ PHARMA GMBh & CO. KGaAInventors: Kevin Kiehm, Bernhard Hauptmeier, Peter Boderke
-
Publication number: 20140161855Abstract: A cosmetic including two different systems for procurement of actives in the human skin and enhancing the collagen I synthesis. The cosmetic with enhanced collagen I synthesis can include 0.001 to 2% by weight, related to the total weight of the cosmetic, of a first retinol-containing system including retinol encapsulated in a chitosan and carboxymethyl cellulose shell, 0.001 to 3.5% by weight, related to the total weight of the cosmetic, of a second retinol-containing system including cationic liposomes composed of phospholipids and with a quaternary fatty acid monoamine with C21-C23 alkyl residue and the difference to 100% by weight of cosmetic subsidiaries. Very small amounts of retinol in combination with both transport systems show a remarkable effect on the synthesis of collagen I in comparison with one or more other known combinations of retinol derivatives or encapsulated systems.Type: ApplicationFiled: July 13, 2012Publication date: June 12, 2014Applicant: Monsanto Technology LLC a corporationInventors: Olivier Doucet, Muriel Pujos, Cécile Robert, Dorothée Bernini
-
Patent number: 8734871Abstract: The present invention relates to the preparation and use of a glycolipid fraction from Oscillatoria Planktothrix sp., for the treatment and/or prevention of bacterial gum diseases primarily caused by: Actinobacillum actinomycetemconcomitans, Porphyromonas gingivalis, Tannerella forsythia, Treponema denticola and even more preferably by Porphyromonas gingivalis. Said gum diseases, in particular gingivitis and periodontitis (pyorrhea), are primarily caused by a pro-inflammatory response to components of P. gingivalis, leading to destruction of periodontal tissue, and are often accompanied by osteoclastogenesis (increased number of osteoclasts responsible for destruction of bone tissue), and by chronic infection.Type: GrantFiled: July 24, 2009Date of Patent: May 27, 2014Assignee: Bluegreen Biotech S.R.L.Inventor: Monica Molteni
-
Patent number: 8734870Abstract: An activatable functionalised Nth generation dendrimer having: a core comprising a first monomer having at least two carboxylic acid functional groups; and N successive generations, where N=0 to 10, wherein each generation comprises: a second monomer having at least two alcohol functional groups, wherein at least one alcohol group is bonded to a carboxylic acid group of the first monomer of the prior generation, and an additional first monomer attached to a second alcohol function group of said second monomer of that generation; and the final generation having attached thereto at said second alcohol functional group of said second monomer, a moiety having a dicarboxylic acid functional group, activatable by treatment with a carboxylic acid activating reagent such that reactivity of the carboxylic acid functional group is increased. The dendrimer, when activated, may be used in applications such as polymer crosslinking and/or nanoshell production.Type: GrantFiled: March 19, 2009Date of Patent: May 27, 2014Assignee: National University of Ireland, GalwayInventors: Abhay Pandit, Gildas Rethore, Hemantkumar Naik
-
Patent number: 8728465Abstract: Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (TLR) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (TLR) ligand; and pulsing a dendentic cell with the at least one TLR ligand. A method further comprises pulsing the dendritic cell with a tumor lysate.Type: GrantFiled: June 17, 2009Date of Patent: May 20, 2014Assignee: Cedars-Sinai Medical CenterInventors: Keith L. Black, Dwain Morris-Irvin, Moshe Arditi
-
Publication number: 20140134135Abstract: The invention provides compositions and methods for preserving lean body mass during weight loss in an animal. The methods comprise administering OEA to the animals, preferably in amounts of from about 0.01 to about 1000 mg/kg/day.Type: ApplicationFiled: May 8, 2012Publication date: May 15, 2014Applicant: NESTEC SAInventors: Delphine Tissot-Favre, Yuanlong Pan
-
Publication number: 20140128256Abstract: Disclosed herein is a Bacillus strain, Bacillus sp. isolate F727, that produces metabolites with pesticidal activities. Also provided are bioactive compositions and metabolites derived from cultures of Bacillus sp. isolate F727 capable of controlling pests; as well as methods of use of the strain and its metabolites for controlling pests.Type: ApplicationFiled: March 15, 2013Publication date: May 8, 2014Applicant: MARRONE BIO INNOVATIONS, INCInventors: Ratnakar Asolkar, Ana-Lucia Cordova-Kreylos, Christopher D McCort, Debora Wilk, Carly Todd, Hai Su, Pamela Marrone
-
Publication number: 20140127286Abstract: The invention refers to a cosmetic composition for increasing collagen synthesis in skin cells comprising 0.001-0.5 wt % of a Phaeodactylum tricornutum extract, 0.00001-2.0 wt % of Dimer Tripeptide-43 or Hydrolyzed Rice Protein, and cosmetic auxiliaries. The cosmetic composition comprising the combination of both components has an synergistic effect on collagen I synthesis in skin cells and has a booster effect to other substances which are known to have an enhancing effect to collagen I synthesis.Type: ApplicationFiled: April 18, 2012Publication date: May 8, 2014Inventors: Olivier Doucet, Muriel Pujos, Cécile Robert, Dorothée Bernini
-
Publication number: 20140127336Abstract: A process for the preparation of a pharmaceutically effective extract from the cyanobacterium Arthrospira spec. having the following steps: extrusion of a powder containing Arthrospira spec. with the addition of water; extraction of the extrudate with an organic solvent; and provision of the extract as a pharmaceutically effective composition.Type: ApplicationFiled: May 4, 2012Publication date: May 8, 2014Applicant: Ocean Research & Development GmbHInventors: Jorg Keimes, Patrick Gunther
-
Patent number: 8715701Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.Type: GrantFiled: November 20, 2007Date of Patent: May 6, 2014Assignee: Instytut Medycyny Doswiadczalnej I KlinicznejInventors: Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska
-
Patent number: 8715754Abstract: Provided are bioactive compounds and metabolites derived from Chromobacterium species culture responsible for controlling pests, compositions containing these compounds, methods for obtaining these compounds and methods of using these compounds and compositions for controlling pests.Type: GrantFiled: October 24, 2011Date of Patent: May 6, 2014Assignee: Marrone Bio Innovations, Inc.Inventors: Ratnakar Asolkar, Huazhang Huang, Marja Koivunen, Pamela Marrone
-
Publication number: 20140120191Abstract: Disclosed herein are methods and compositions for treating a disorder associated with sequestered bacteria in a mammalian subject comprising the step of administering to the subject a combination therapy comprising streptolysin O and antibiotic therapy in an amount effective to treat the disorder.Type: ApplicationFiled: January 26, 2012Publication date: May 1, 2014Applicant: BEECH TREE LABS INC.Inventor: John McMichael
-
Publication number: 20140120141Abstract: Peptides of general formula (I), their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use for the treatment and/or care of conditions, disorders and/or diseases of the skin and/or mucous membranes.Type: ApplicationFiled: March 23, 2012Publication date: May 1, 2014Applicant: LIPOTEC S.A.Inventors: José María García Antón, Nuria Almiñana Domenech, Antonio Vicente Ferrer Montiel
-
Publication number: 20140113015Abstract: The invention relates to a novel strain of Schizochytrium sp. that can produce large quantities of squalene, the methods for the production of lipid compounds of interest using said strain and the products and compositions prepared with said strain.Type: ApplicationFiled: May 18, 2012Publication date: April 24, 2014Applicant: ROQUETTE FRERESInventors: Bernard Pora, Jie Zhou, Sophie Defretin, Xavier Vandewalle
-
Publication number: 20140112897Abstract: The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.Type: ApplicationFiled: June 8, 2012Publication date: April 24, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: David Pyne, Nicholas West, Allan Cripps, Sampo Lahtinen
-
Publication number: 20140106016Abstract: The present invention relates to the cosmetic use of a lysate of a bacterium or bacteria belonging to the Vitreoscilla sp. genus (in particular the species: Vitreoscilla filiformis) in a complete fermentation medium, as an active agent for preventing and/or treating dandruff conditions of the scalp, including dandruff conditions of the scalp associated with a prevalence of pathogenic microorganisms on the scalp and/or an imbalance of the scalp ecoflora.Type: ApplicationFiled: April 5, 2012Publication date: April 17, 2014Applicant: L'OREALInventors: Pascal Hilaire, Yann Mahe, Richard Martin
-
Publication number: 20140105864Abstract: Oral compositions comprising an association of one or of a mixture of phytoestrogens, selective for the estrogen receptor-?, with dietary fibres are described. The compositions thereof can be profitably used for the prophylactic and therapeutic treatment in mammals, including humans, of health conditions characterised by a high risk of onset and recurrence of intestinal adenomas (adenopolyposis coli), and of adenoma's progression to colorectal carcinoma. In presence of pre-cancerous lesions in the colon, characterised by mutations of the APC tumor suppressor and defined as polyps or adenomas, the oral compositions disclosed can be in fact profitably used to reduce the number and volume of polyps, and to prevent their progression to neoplastic transformation, reducing their degree of dysplasia.Type: ApplicationFiled: December 13, 2013Publication date: April 17, 2014Applicant: CM & D PHARMA LIMITEDInventor: Alfredo DI LEO
-
Publication number: 20140105972Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.Type: ApplicationFiled: November 21, 2013Publication date: April 17, 2014Applicant: Mayo Foundation for Medical Education and ResearchInventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam